본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

European journal of medicinal chemistry v.143, 2018년, pp.1790 - 1806   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity

Negmeldin, Ahmed T. (Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202, United States ) ; Knoff, Joseph R. (Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202, United States ) ; Pflum, Mary Kay H. (Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202, United States ) ;
  • 초록  

    Abstract Histone deacetylase (HDAC) enzymes govern the post-translational acetylation state of lysine residues on protein substrates, leading to regulatory changes in cell function. Due to their role in cancers, HDAC proteins have emerged as promising targets for cancer treatment. Four HDAC inhibitors have been approved as anti-cancer therapeutics, including SAHA (Suberoylanilide hydroxamic acid, Vorinostat, Zolinza). SAHA is a nonselective HDAC inhibitor that targets most of the eleven HDAC isoforms. The nonselectivity of SAHA might account for its clinical side effects, but certainly limits its use as a chemical tool to study cancer-related HDAC cell biology. Herein, the nonselective HDAC inhibitor SAHA was modified at the C4 position of the linker to explore activity and selectivity. Several C4-modified SAHA analogs exhibited dual HDAC6/8 selectivity. Interestingly, ( R )-C4-benzyl SAHA displayed 520- to 1300-fold selectivity for HDAC6 and HDAC8 over HDAC1, 2, and 3, with IC 50 values of 48 and 27 nM with HDAC6 and 8, respectively. In cellulo testing of the inhibitors was consistent with the observed in vitro selectivity. Docking studies provided a structural rationale for selectivity. The C4-SAHA analogs represent useful chemical tools to understand the role of HDAC6 and HDAC8 in cancer biology and exciting lead compounds for targeting of both HDAC6 and HDAC8 in various cancers. Highlights Analogs of non-selective FDA-approved drug SAHA (Vorinostat) demonstrated selectivity for HDAC6 and 8 over HDAC1, 2, and 3. The best compound, ( R )-C4-benzyl SAHA, displayed IC 50 values of 48 and 27 nM with HDAC6 and HDAC8, respectively. ( R )-C4-benzyl SAHA maintained 520- to 1300-fold selectivity for HDAC6 and HDAC8. The HDAC6 selectivity of C4-benzyl SAHA was reproduced in cancer cells. Docking studies provided a structural rationale for the HDAC6/HDAC8 selectivity of C4-benzyl SAHA. Graphical abstract [DISPLAY OMISSION]


  • 주제어

    Histone deacetylase .   HDAC inhibitor .   Dual HDAC6/HDAC8 selective inhibitor .   SAHA (Vorinostat) .   HDAC isoform selectivity.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기